Viatris Inc. announced a definitive agreement to sell its equity stake in Biocon Biologics Limited to Biocon Limited for $815 million. The deal, comprised of $400 million in cash and $415 million in newly issued equity shares of Biocon, will accelerate the expiration of biosimilars non-compete restrictions for Viatris. The transaction is expected to finalize in the first quarter of 2026.

暉致

<p>Viatris Inc. 宣佈與 Biocon Limited 達成一項最終協議，以 8.15 億美元的價格出售其在 Biocon Biologics Limited 的股權。該交易包括 4 億美元現金和 4.15 億美元的新發行 Biocon 股份，將加速 Viatris 生物類似藥的非競爭限制的到期。該交易預計將在 2026 年第一季度完成</p>

Viatris To Sell Equity Stake In Biocon Biologics To Biocon For $815 Mln